Gene · 4261
Papers3,496
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
341 to 360 of 3,496
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Involvement of the SIRT1-NLRP3 pathway in the inflammatory response. | Cell Commun Signal | 2023 | 37507744 | PubTator, text mining | PubMed |
| Expanding the Horizons of Pre-Transplant Renal Vascular Assessment Using Ex Vivo Perfusion. | Curr Issues Mol Biol | 2023 | 37504261 | PubTator, text mining | PubMed |
| Integrated Multi-omics Analysis of Early Lung Adenocarcinoma Links Tumor Biological Features with Predicted Indolence or Aggressiveness. | Cancer Res Commun | 2023 | 37501683 | PubTator, text mining | PubMed |
| Immunopeptidome profiling of human coronavirus OC43-infected cells identifies CD4 T-cell epitopes specific to seasonal coronaviruses or cross-reactive with SARS-CoV-2. | PLoS Pathog | 2023 | 37498934 | PubTator, text mining | PubMed |
| Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma. | Front Immunol | 2023 | 37492563 | PubTator, text mining | PubMed |
| Genetic Factors in Familial Manifestation of Primary Mediastinal Large B-Cell Lymphoma over Two Generations. | Pathobiology | 2023 | 37490879 | PubTator, text mining | PubMed |
| Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial. | Nat Med | 2023 | 37488287 | PubTator, text mining | PubMed |
| The NLR member CIITA: Master controller of adaptive and intrinsic immunity and unexpected tool in cancer immunotherapy. | Biomed J | 2023 | 37467968 | PubTator, text mining | PubMed |
| Regulation of SARS-CoV-2 infection by diet-modulated gut microbiota. | Front Cell Infect Microbiol | 2023 | 37457959 | PubTator, text mining | PubMed |
| Maternal hepatic immunology during pregnancy. | Front Immunol | 2023 | 37457700 | PubTator, text mining | PubMed |
| A tumor mutational burden-derived immune computational framework selects sensitive immunotherapy/chemotherapy for lung adenocarcinoma populations with different prognoses. | Front Oncol | 2023 | 37456238 | PubTator, text mining | PubMed |
| Type 1 and type 2 cytokine-mediated immune orchestration in the tumour microenvironment and their therapeutic potential. | Explor Target Antitumor Ther | 2023 | 37455828 | PubTator, text mining | PubMed |
| Resistance to immune checkpoint therapies by tumour-induced T-cell desertification and exclusion: key mechanisms, prognostication and new therapeutic opportunities. | Br J Cancer | 2023 | 37454231 | PubTator, text mining | PubMed |
| Melanoma Cells Inhibit iNKT Cell Functions via PGE2 and IDO1. | Cancers (Basel) | 2023 | 37444608 | PubTator, text mining | PubMed |
| Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy. | Cancers (Basel) | 2023 | 37444586 | PubTator, text mining | PubMed |
| Identification of angiogenesis-related genes signature for predicting survival and its regulatory network in glioblastoma. | Cancer Med | 2023 | 37434432 | PubTator, text mining | PubMed |
| Synthesizing a Smarter CAR T Cell: Advanced Engineering of T-cell Immunotherapies. | Cancer Immunol Res | 2023 | 37429007 | PubTator, text mining | PubMed |
| In vivo CRISPR/Cas9 screening identifies Pbrm1 as a regulator of myeloid leukemia development in mice. | Blood Adv | 2023 | 37428871 | PubTator, text mining | PubMed |
| Identification and validation of m6A-GPI signatures as a novel prognostic model for colorectal cancer. | Front Oncol | 2023 | 37427112 | PubTator, text mining | PubMed |
| Restoring tumor immunogenicity with dendritic cell reprogramming. | Sci Immunol | 2023 | 37418548 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4261/papers?page=18